The telomerase inhibitor imetelstat differentially targets JAK2V617F versus CALR mutant myeloproliferative neoplasm cells and inhibits JAK-STAT signaling

Imetelstat shows activity in patients with myeloproliferative neoplasms, including primary myelofibrosis (PMF) and essential thrombocythemia. Here, we describe a case of prolonged disease stabilization by imetelstat treatment of a high-risk PMF patient enrolled into the clinical study MYF2001. We co...

Descripción completa

Detalles Bibliográficos
Autores principales: Olschok, Kathrin, Altenburg, Bianca, de Toledo, Marcelo A. S., Maurer, Angela, Abels, Anne, Beier, Fabian, Gezer, Deniz, Isfort, Susanne, Paeschke, Katrin, Brümmendorf, Tim H., Zenke, Martin, Chatain, Nicolas, Koschmieder, Steffen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10628476/
https://www.ncbi.nlm.nih.gov/pubmed/37941547
http://dx.doi.org/10.3389/fonc.2023.1277453

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10628476/
https://www.ncbi.nlm.nih.gov/pubmed/37941547
http://dx.doi.org/10.3389/fonc.2023.1277453

Ejemplares similares